Breast Cancer: Current Research
Open Access

Microbiota; Breast cancer; Gut microbiome; Mammary microbiota; Microbial dysbiosis; Oncobiome; Tumor microenvironment; Probiotics; Immune modulation; Therapeutic interventions; Microbial metabolites; Biomarkers

Introduction

The human microbiota, consisting of bacteria, viruses, fungi, and other microorganisms inhabiting various anatomical sites, plays a crucial role in maintaining host homeostasis and modulating immune responses. Dysbiosis, or alterations in the composition and function of the microbiota, has been implicated in the pathogenesis of several diseases, including cancer. In recent years, growing evidence suggests that the microbiota may also play a role in breast cancer, the most common cancer among women worldwide. Understanding the interplay between the microbiota and breast cancer holds significant implications for disease prevention, diagnosis [1,2].

Methodology

Breast cancer continues to be a significant global health challenge, affecting millions of women worldwide. Despite advances in detection and treatment, the intricacies of its development remain elusive. Recent research has spotlighted the microbiota's influence on various aspects of health, including cancer. The microbiota, comprising trillions of microbes residing in and on the human body, has emerged as a crucial player in modulating immune responses, inflammation, and metabolism, all of which are intricately linked to cancer development. Understanding the interplay between the microbiota and breast cancer offers novel insights into its etiology and opens avenues for innovative therapeutic strategies [3].

Microbiota dysbiosis and breast cancer risk: Dysbiosis, an imbalance in the composition and function of the microbiota, has been implicated in numerous diseases, including cancer. In breast cancer, dysbiosis in the gut, breast tissue, and mammary gland microbiota has been observed. Several factors contribute to microbiota dysbiosis, including diet, lifestyle, antibiotic use and hormonal fluctuations. Dysbiosis can lead to chronic inflammation, altered immune responses, and metabolic disturbances, creating a microenvironment conducive to tumor initiation and progression [4].

Immune modulation by the microbiota: The microbiota plays a pivotal role in shaping immune responses, influencing the balance between pro-inflammatory and anti-inflammatory pathways. Dysbiotic microbiota can trigger chronic inflammation, promoting tumor growth and metastasis. Conversely, a healthy microbiota fosters immune tolerance and surveillance, limiting tumor proliferation [5]. Understanding how specific microbial populations modulate immune function in breast tissue holds promise for immunotherapeutic interventions tailored to individual microbiota profiles.

Metabolic influences: Metabolites produced by the microbiota exert profound effects on host physiology, including energy metabolism, hormone regulation, and immune function. Short-chain fatty acids (SCFAs), produced through the fermentation of dietary fibers by gut bacteria, have been implicated in breast cancer prevention by inhibiting tumor cell proliferation and promoting apoptosis [6]. Conversely, microbial metabolism of dietary components such as choline and carnitine can generate metabolites associated with increased breast cancer risk. Targeting microbial metabolic pathways offers a novel approach for manipulating the tumor microenvironment and enhancing treatment efficacy.

Therapeutic opportunities: Harnessing the microbiota as a therapeutic target in breast cancer holds immense promise. Strategies aimed at restoring microbiota balance, such as probiotics, prebiotics, and fecal microbiota transplantation (FMT), have shown potential in preclinical studies and early-phase clinical trials. Personalized approaches that consider individual microbiota composition and host factors offer a tailored approach to treatment [7]. Additionally, microbiota-based adjuvants could enhance the efficacy of existing therapies, such as chemotherapy, immunotherapy and hormone therapy, by modulating treatment responses and reducing side effects.   

Applications: Personalized treatment strategies: Understanding the role of microbiota in breast cancer can lead to the development of personalized treatment strategies tailored to an individual's unique microbiome profile [8].

Improved diagnosis and prognosis: Utilizing microbiota analysis alongside traditional diagnostic methods can enhance the accuracy of breast cancer diagnosis and provide valuable prognostic information.

Preventive measures: Insights into the microbiota's role may enable the development of preventive measures such as dietary interventions, lifestyle modifications, or targeted microbial therapies to reduce breast cancer risk [9].

Enhanced therapeutic efficacy: Manipulating the microbiota composition could enhance the efficacy of conventional cancer treatments such as chemotherapy, immunotherapy or radiation therapy, potentially improving patient outcomes.

Minimizing treatment side effects: Understanding how the microbiota influences treatment-related side effects (e.g., chemotherapy-induced gastrointestinal toxicity) could lead to interventions to alleviate these adverse effects and improve patient quality of life [10].

Identification of biomarkers: Specific microbial signatures associated with breast cancer could serve as biomarkers for early detection, prognostication, and monitoring treatment response.

Exploration of novel therapeutic targets: Targeting key microbial species or pathways implicated in breast cancer development and progression could lead to the discovery of novel therapeutic targets for drug development.

Enhanced immunotherapy response: Modulating the microbiota may enhance the response to immunotherapy by promoting anti-tumor immune responses and overcoming treatment resistance mechanisms.

Promotion of healthy microbiota: Promoting a healthy microbiota through dietary interventions, probiotics, or fecal microbiota transplantation may have a protective effect against breast cancer development or recurrence.

Integration into clinical practice: Incorporating microbiota analysis into routine clinical practice could revolutionize breast cancer management by providing clinicians with valuable information for personalized treatment decision-making.

Discussion

Despite the growing evidence implicating the microbiota in breast cancer, several challenges remain. The complex and dynamic nature of the microbiota, coupled with inter-individual variability, necessitates large-scale longitudinal studies to unravel its precise role in breast cancer development and progression. Standardization of methodologies for microbiota analysis and integration of multi-omics data are essential for advancing our understanding of microbiota-cancer interactions. Moreover, ethical considerations and safety concerns surrounding microbiota-based interventions warrant careful evaluation and regulatory oversight.

Conclusion

The microbiota represents a dynamic and multifaceted player in the complex landscape of breast cancer. Understanding its role in tumor initiation, progression, and treatment response offers new avenues for therapeutic intervention. By modulating the microbiota, we have the potential to reshape the tumor microenvironment, enhance immune surveillance, and improve treatment outcomes. Collaborative efforts across disciplines are needed to translate microbiota research into clinically actionable strategies, ultimately improving the lives of individuals affected by breast cancer.

References

1. SchnorrenbergF (1996) Comparison of Manual and Computer-Aided Breast Cancer Biopsy Grading. Conf Proc IEEE Eng Med Biol Soc 3: 1166-1167.

Indexed at, Google Scholar, Crossref

2. Chinen AB, Guan CM, Jennifer JR, Barnaby SN, Merkel TJ, et.al (2015) Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence. Chem Rev 115: 10530-10574.

Indexed at, Google Scholar, CrossRef

3. Azzouz A, Hejji L, Kim K-H, Kukkar D, Souhail B, et.al (2022) Advances in Surface Plasmon Resonance-Based Biosensor Technologies for Cancer Biomarker Detection. Biosens Bioelectron 197: 113767

Indexed at, Google Scholar, CrossRef

4. Williams BJ, DaCosta P, Goacher E, Treanor D (2017) ASystematic Analysis of Discordant Diagnoses in Digital Pathology Compared with Light Microscopy. Arch Pathol Lab Med 141: 1712-1718.

Indexed at, Google Scholar, Crossref

5.  Janowczyk A, Madabhushi A (2016) Deep Learning for Digital Pathology Image Analysis: A Comprehensive Tutorial with Selected Use Cases. JPathol Inform 7: 29.

Indexed at, Google Scholar, Crossref

6. Robertson S, Azizpour H, Smith K, Hartman J (2018) Digital Image Analysis in Breast Pathology-from Image Processing Techniques to Artificial Intelligence. Transl Res 194: 19-35.

Indexed at, Google Scholar, Crossref

7. Sung H , Ferlay J, Siegel R.L, Laversanne M, Soerjomataram I, et.al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Ca Cancer J Clin 71: 209-249.

Indexed at, Google Scholar, CrossRef

8. Ulucan-Karnak F, Akgöl S (2021) A New Nanomaterial Based Biosensor for MUC1 Biomarker Detection in Early Diagnosis, Tumor Progression and Treatment of Cancer. Nanomanufacturing 1: 14-38

Indexed at, Google Scholar, CrossRef

9. Li X, Ma F, Yang M, Zhang J, (2022) Nanomaterial Based Analytical Methods for Breast Cancer Biomarker Detection. Mater. Today Adv 14: 100219.

Indexed at, Crossref

10. Chekkoury A, Khurd P, Ni J, Bahlmann C, Kamen A, et al. (2012) Automated Malignancy Detection in Breast Histopathological Images. SPIE Medical Imaging 8315.

Indexed at, Google Scholar, Crossref